Search PubMed⌕ Search

Biomedical subjects

C Haanen

Publications and source records attributed to C Haanen.

At least 217 records · Page 12Linked to original sources
PubMed1976

The influence of splenectomy on cellular immunologic parameters in Hodgkin's disease.

Cellular immunity was evaluated in 15 untreated patients with Hodgkin's disease before and about 10 days after splenectomy. Skin test-reactivity was not affected by the operation. The number of lymphocytes was moderately increased in patients with pathologic stage I and II disease. The relative proportion of E-binding lymphocytes in the peripheral blood diminished significantly (p = .001) in patients with splenic weights of 240 g and more, whereas the PHA-stimulated thymidine incorporation increased significantly (p = .015) and the proportion of EAC-binding lymphocytes increased significantly (p = .023). The PHA-stimulation of peripheral lymphocytes in patients with pathologic stage I and II disease was at the same level before and after operation, but increased significantly (less than 0.02) in the more disseminated forms. The stimulation of the lymphocytes in vitro by a cocktail of antigens, and by allogeneic cells (MLC) remained unchanged. Although the number of cases studied is rather small, it is concluded that about 10 days after, splenectomy has no demonstrable untoward effect on the cellular immunologic potency.

Adolescent↗
PubMed1975

"Incubation period" in Hodgkin's disease.

Two clusters of patients with Hodgkin's disease are described. The interval between the first contact of the secondary cases with the index cases and the appearance of symptoms suggested a maximum "incubation" period of 2-6 months.

Adult↗
PubMed1975

Bone-marrow-profileration patterns in acute myeloblastic leukaemia determined by pulse cytophotometry.

The proliferation patterns of normal and leukaemic bone-marrow were studied by measuring the D.N.A. content of large numbers of cells by pulse cytophotometry (P.C.P.). In nineteen normal bone-marrow samples an average of 66-3% of the bone-marrow cells were in the G1 phase (2n D.N.A.), 26-1% in the S phase (2n smaller than D.N.A. smaller than 4n), and 7-5% in G2+M phase (4n D.N.A.). The percentages of S-phase cells determined by autoradiography and P.C.P. correlated well, both in normal and in leukaemic bone-marrow. In 25 patients with untreated acute myeloblastic leukaemia (A.M.L.) lower percentages of cells were found in S and G2+M phases, indicating a smaller proliferating pool compared with normal bone-marrow. The likelihood of a complete remission being attained in A.M.L. with the first treatment course was correlated with the percentage of S-phase cells present before treatment. At remission in A.M.L. the proliferation pattern was restored to normal.

Autoradiography↗
PubMed1975

Treatment of acute lymphoblastic leukemia in adolescents and a-dults: A retrospective study of 41 patients (1970-1973).

During the period from January 1970 until December 1973, therapy was started in 41 previously untreated adolescents and adults with acute lymphoblastic leukemia. Induction therapy was started with vincristine and prednisone in all patients, resulting in complete remission in 19 and death due to infection during the first month in one case. After 3 wk on these two drugs, the addition of daunorubicin was required in the remaining 21 patients. Fifteen of these obtained remission, one died during induction therapy, and five patients were unresponsive to this therapy, as well as to all subsequent induction schemes. The overall remission rate was 83%. Significantly higher initial leukocyte counts were found in the group treated with vincristine, prednisone, and daunorubicin. Meningeal leukemia prophylaxis, by either periodic methotrexate injections given intrathecally or a combination of cranial irradiation and intrathecally administrated methotrexate, was administered in 29 therapy responders. The median duration of complete remission obtained with various maintenance therapy schemes was 13 mo. No differences were seen in the results obtained in patients between 14 and 20 yr of age and older patients. Twenty-two patients relapsed within 2-37 mo. Relapses were confined to the central nervous system in two cases, to the bone marrow in 18, and to the bone marrow and CNS simultaneously in two. A second remission was obtained in 17 cases (77%). The median survival time of the whole group was 27 mo, as compared with 32 mo for therapy responders and 7 mo for the nonresponders. The percentage and duration of remission and the survival time in our group of adolescents and adults were comparable to those currently being achieved in other centers, but not as good as those reported for children treated with the same protocols.

Adolescent↗